269
Views
7
CrossRef citations to date
0
Altmetric
REVIEW

Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver

, , , , , , , & ORCID Icon show all
Pages 3829-3845 | Received 20 Aug 2022, Accepted 25 Oct 2022, Published online: 05 Dec 2023

Figures & data

Figure 1 The mechanisms of CD36 in NAFLD. (A). Molecular mechanisms by which CD36 palmitoylation promotes FAO and NAFLD. (B). Molecular mechanisms by which CD36 palmitoylation promotes β-oxidation and inflammation. (C). Molecular mechanisms by which CD36 inhibits autophagy. (D). Molecular mechanisms by which CD36 promotes De novo lipogenesis.

Abbreviations: NAFLD, nonalcoholic fatty liver disease; CD36, differentiated cluster 36; LCFA, long chain fatty acid; ACSL, long-chain acyl-CoA synthetase; FAO, free fatty acid oxidation; TG, triglycerides; LKB1, live kinase B1; JNK, c-JUN N-terminal kinase; AMPK, AMP-activated protein kinase; Lyn, the kinase Lck/Yes-related novel protein tyrosine kinase; FA, Fatty acid; AhR, aryl hydrocarbon receptor; PXR, Pregnane X receptor; PPARγ: peroxisome proliferator-activated receptorγ; LXR, liver X receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; mTOR, mechanistic target of rapamycin; UCK1, uridine-cytidine kinase 1; LDs, lipid droplets; ER, endoplasmic reticulum; SCAP, SREBP cleavage-activating protein; INSIG2, insulin-induced gene-2; SREBP1, sterol regulatory element-binding protein 1.
Figure 1 The mechanisms of CD36 in NAFLD. (A). Molecular mechanisms by which CD36 palmitoylation promotes FAO and NAFLD. (B). Molecular mechanisms by which CD36 palmitoylation promotes β-oxidation and inflammation. (C). Molecular mechanisms by which CD36 inhibits autophagy. (D). Molecular mechanisms by which CD36 promotes De novo lipogenesis.

Table 1 Natural products which treat NAFLD through CD36